EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial

Rupsa C Boelig iD, Avinash Kavi iD, Janet L Moore, Denise C Babineau, Mrityunjay C Metgud, Manjunath S Somannavar, Shivaprasad S Goudar, Richard J Derman, Shiyam Sunder Tikmani, Sarah Saleem, Robert L Goldenberg, Adrien L Lokangaka und 20 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 2026

DOI: 10.1111/1471-0528.70121 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2026. Verfasst von Rupsa C Boelig und 31 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College - Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Azithromycin, Anti-Bacterial Agents, Pregnancy Complications, Infectious, Antibiotic Prophylaxis. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Bill & Melinda Gates Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A multi‐centre international trial (A‐PLUS), demonstrated that a single dose of 2 g oral azithromycin in labour reduced the risk of maternal sepsis or death, but not neonatal mortality. We aimed to determine whether the efficacy of azithromycin in prevention of any maternal infection or neonatal infection varied by time interval from azithromycin administration to delivery.

Design

This is a secondary analysis of a randomized controlled trial.

Setting

Multi‐centre international randomized controlled trial. Population Pregnant patients ≥ 28 weeks gestation (singleton or multiple gestation) presenting in labour for planned vaginal delivery. Outcomes The primary outcome for this secondary analysis was maternal infection and the secondary outcome was any neonatal infection.

Methods

The estimated relative risks (and 95% confidence interval) of any maternal or neonatal infection comparing azithromycin to placebo were obtained by fitting a Poisson model adjusting for site, treatment arm, hours between drug administration and delivery (as continuous measure, and ≤ 12 or > 12 h for maternal and ≤ 9 or > 9 h for neonatal), and the two‐way interaction between treatment arm and hours between drug administration and delivery.

Results

Included in the analysis were n = 14 569 randomized to azithromycin and n = 14 667 to placebo. There was no evidence that the benefit of azithromycin on reducing the risk of any maternal infection varied by time from dose to delivery (RR 0.71 (0.64–0.79) and RR 0.71 (0.54–0.94) for ≤ 12 and > 12 h respectively, interaction p = 0.987), although there was an observed interaction in Sub‐Saharan Africa subgroup with reduced risk observed with administration > 12 vs. ≤ 12 (RR 0.21 (0.08–0.54) vs. RR 0.52 (0.41–0.66), interaction p = 0.03). There was no benefit observed in prevention of infant infection regardless of time from dose to delivery (≤ 9 or > 9 h) (RR 1.00 (0.95–1.06) and RR 1.01 (0.88–1.15) interaction p = 0.997).

Conclusion

The benefit observed with a single intrapartum dose of azithromycin for prevention of any maternal infection in the setting of planned vaginal delivery was not observed to vary by time interval from azithromycin administration to delivery, although in some populations there may be greater benefit with delivery > 12 h from administration. Pregnant patients presenting for planned vaginal birth benefit from a single dose of 2 g azithromycin regardless of how soon delivery is anticipated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAnti-Bacterial AgentsPregnancy Complications, InfectiousAntibiotic ProphylaxisInfectious Disease Transmission, VerticalHumansFemalePregnancyInfant, NewbornAdultDrug Administration ScheduleDelivery, Obstetric

Stichwörter der Autor:innen

antibioticsazithromycinlabourmaternal infectionperinatal infection

Substanzen

AzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Sidney Kimmel Medical College - Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.
  • RTI International, Research Triangle Park, North Carolina, USA.
  • Aga Khan University, Karachi, Sindh, Pakistan.
  • Columbia University School of Medicine, New York, New York, USA.
  • Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.

ORCID-Profile: Rupsa C Boelig, Avinash Kavi, Archana B Patel, Sk Masum Billah, Elizabeth M McClure, Waldemar A Carlo

Förderung

  • NICHD NIH HHS
  • Bill & Melinda Gates Foundation
  • NIH HHS
  • Foundation for the National Institutes of Health
  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Boelig, R. C., Kavi, A., Moore, J. L., Babineau, D. C., Metgud, M. C., Somannavar, M. S., Goudar, S. S., Derman, R. J., Sunder Tikmani, S., Saleem, S., Goldenberg, R. L., Lokangaka, A. L., Tshefu, A. K., Bauserman, M. S., Mwenechanya, M., Chomba, E., Mazariegos, M., Figueroa, L., Krebs, N. F., …, & APLUS Trial Group (2026). Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.70121

Vancouver

Boelig RC, Kavi A, Moore JL, Babineau DC, Metgud MC, Somannavar MS, et al. Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2026. doi:10.1111/1471-0528.70121

BibTeX
@article{Boelig2026,
  author = {Boelig, Rupsa C and Kavi, Avinash and Moore, Janet L and Babineau, Denise C and Metgud, Mrityunjay C and Somannavar, Manjunath S and Goudar, Shivaprasad S and Derman, Richard J and Sunder Tikmani, Shiyam and Saleem, Sarah and Goldenberg, Robert L and Lokangaka, Adrien L and Tshefu, Antoinette K and Bauserman, Melissa S and Mwenechanya, Musaku and Chomba, Elwyn and Mazariegos, Manolo and Figueroa, Lester and Krebs, Nancy F and Nyongesa, Paul and Esamai, Fabian and Bucher, Sherri and Patel, Archana B and Hibberd, Patricia L and Petri, William A and Billah, Sk Masum and Haque, Rashidul and Koso-Thomas, Marion and McClure, Elizabeth M and Carlo, Waldemar A and Tita, Alan T N and APLUS Trial Group, APLUS Trial Group},
  title = {Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2026},
  doi = {10.1111/1471-0528.70121}
}
Kostenlos starten →